NEUROCHEM ENROLLS FIRST PATIENT IN ALZHEIMER'S TRIAL

Neurochem announced that the first patient in its European Phase III clinical trial of Alzhemed has been enrolled at the Middelheim Ziekenhuis center in Belgium. Alzhemed is Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD).

The ongoing clinical trial, a multicenter, randomized, double-blind, placebo-controlled and parallel-designed study, is on schedule and will investigate the safety and efficacy of Alzhemed in treating AD, with some 930 mild-to-moderate AD patients expected to take part. They will be randomized to receive either placebo or one of two different dose levels of Alzhemed for a period of 18 months, in addition to their regular treatment with one of a number of acetylcholinesterase inhibitors.